Myosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 106
Recruiting: 58
Ph III recruiting: 6
Growth YoY: −35%
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (42)

clinicaltrialsPublishedShowing 151–166 of 166 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00093080	Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)	completed	Phase 2	216	Merck Sharp & Dohme LLCINDUSTRY	0	Feb 13, 2015	clinicaltrials
NCT00282087	Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma	completed	Phase 2	47	Sarcoma Alliance for Research through CollaborationOTHER	1	Dec 1, 2014